New avenue for treating breast cancer

March 29, 2016

"With the support of the National Cancer Institute, CITN has established a network of top academic immunologists to conduct multicenter research on promising new agents that boost patients' own immune systems to fight their cancer," said Principal Investigator Martin A. "Mac" Cheever, M.D., a member of the Hutchinson Center's Clinical Research Division and director of CITN. "Having selected CYT107 along with other promising molecules for testing in patients, we now look forward to conducting clinical studies that follow a pathway whose ultimate goal is to make effective immunotherapy agents broadly available for treatment of cancer."

CITN will select and prioritize proposals for clinical study regimens based on the following criteria:

Regimens with clear immunologic endpoints likely to inform the next phases of drug development??specifically, those that prospectively and predictably increase the number of T cells specific for known and defined antigens; Developing regimens that can be applied in multiple circumstances by multiple investigators; Providing high-quality immunogenicity and biomarker data that elucidate mechanisms of response or failure and thereby facilitate the design of subsequent trials.

Source: Cancer Immunotherapy Trials Network (CITN)